Contraception Clinical Trial
Official title:
The Effects of the Female Sex Hormones and Hormonal Contraception on Cerebral Perfusion
Measuring brain perfusion is biased by a inter- and intrasubject variability, caused by physiological and lifestyle factors. In this study, the investigators want to investigate the variations in cerebral perfusion and other brain parameters (grey matter, resting-state brain activity, brain connectivity and white matter diffusion) caused by the female sex hormones and hormonal contraception.
Status | Recruiting |
Enrollment | 62 |
Est. completion date | December 31, 2027 |
Est. primary completion date | December 31, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: - Bachelor or Master student - Minimum of 3 months not using contraception of using Deso20 Exclusion Criteria: - No informed consent - MRI-contraindications - Claustrophobia - Pregnancy or breastfeeding - Chronic diseases and chronic medication use - Smoker - Drug use - Abuse of alcohol and caffeine |
Country | Name | City | State |
---|---|---|---|
Belgium | Ghent University Hospital | Ghent |
Lead Sponsor | Collaborator |
---|---|
University Ghent |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Regional cerebral perfusion (ml/100g/min): natural versus contraception | Differences in regional perfusion between volunteers of the natural cycle group versus the volunteers using contraception | measured during scan-session | |
Primary | Regional cerebral perfusion (ml/100g/min) variations during natural menstrual cycle | Variations in cerebral perfusion during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample | measured during scan-session | |
Primary | Regional cerebral perfusion (ml/100g/min) variations during menstrual cycle using contraception | Variations in cerebral perfusion during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample | measured during scan-session | |
Secondary | Regional grey matter volume (mm³): natural versus contraception | Differences in regional grey matter volume between volunteers of the natural cycle group versus the volunteers using contraception | measured during scan-session | |
Secondary | Regional grey matter volume (mm³) variations during natural menstrual cycle | Variations during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample | measured during scan-session | |
Secondary | Regional grey matter volume (mm³) variations during menstrual cycle using contraception | Variations in grey matter volume during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample | measured during scan-session | |
Secondary | Resting state brain activity: natural versus contraception | Differences in resting state brain activity between volunteers of the natural cycle group versus the volunteers using contraception | measured during scan-session | |
Secondary | Resting state brain activity variations during natural menstrual cycle | Variations in resting state brain activity during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample | measured during scan-session | |
Secondary | Resting state brain activity variations during menstrual cycle using contraception | Variations in resting state brain activity during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample | measured during scan-session | |
Secondary | Cerebral diffusion properties: natural versus contraception | Differences in diffusion properties (Mean Diffusivity(MD)/Apparent Diffusion Coefficient (ADC)/fractional Anisotropy(FA)) between volunteers of the natural cycle group versus the volunteers using contraception | measured during scan-session | |
Secondary | Cerebral diffusion properties variations during natural menstrual cycle | Variations in diffusion properties (MD/ADC/FA) during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample | measured during scan-session | |
Secondary | Cerebral diffusion properties variations during menstrual cycle using contraception | Variations in diffusion properties (MD/ADC/FA) during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample | measured during scan-session |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |